{"classes":[{"categories":[{"measurements":[{"comment":"SD data not applicable as only one participant was evaluable for this time point.","groupId":"OG001","spread":"NA","value":"-40.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"CFB at Follow-up Month 2"},{"categories":[{"measurements":[{"comment":"SD data not applicable as only one participant was evaluable for this time point.","groupId":"OG000","spread":"NA","value":"5.00"},{"groupId":"OG001","spread":"19.61","value":"5.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"CFB at Follow-up Month 4"},{"categories":[{"measurements":[{"comment":"SD data not applicable as only one participant was evaluable for this time point.","groupId":"OG000","spread":"NA","value":"5.00"},{"groupId":"OG001","spread":"19.00","value":"6.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"title":"CFB at Follow-up Month 6"},{"categories":[{"measurements":[{"comment":"SD data not applicable as only one participant was evaluable for this time point.","groupId":"OG000","spread":"NA","value":"5.00"},{"groupId":"OG001","spread":"17.18","value":"4.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"title":"CFB at Follow-up Month 8"},{"categories":[{"measurements":[{"comment":"SD data not applicable as only one participant was evaluable for this time point.","groupId":"OG000","spread":"NA","value":"-15.00"},{"groupId":"OG001","spread":"16.28","value":"4.62"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"title":"CFB at Follow-up Month 10"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"16.04","value":"5.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"title":"CFB at Follow-up Month 12"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"17.36","value":"5.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"title":"CFB at Follow-up Month 14"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"17.44","value":"6.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"title":"CFB at Follow-up Month 16"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"19.44","value":"6.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"CFB at Follow-up Month 18"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"15.43","value":"7.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"title":"CFB at Follow-up Month 20"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"15.55","value":"6.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"title":"CFB at Follow-up Month 22"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"16.23","value":"8.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"title":"CFB at Follow-up Month 24"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"14.91","value":"4.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"CFB at Final Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"158"}],"units":"Participants"}],"description":"EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Data for this outcome was planned to be reported only for 'Obinutuzumab + Bendamustine' arm. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction). Follow-up months were during maintenance phase.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"MEAN","populationDescription":"ITT population (Obinutuzumab + Bendamustine arm only). Here, number of participants analyzed signified those participants who were evaluable for this outcome and \"n\" signified those participants who were evaluable for a specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction) (end of induction = up to Month 6)","title":"CFB in EQ-5D VAS Score During Maintenance Phase","type":"SECONDARY","unitOfMeasure":"units on a scale"}